CITED2 is highly-expressed and PRX4 is poorly-expressed in preeclampsia and have diagnostic values.

This study aims to investigate the differential level of CITED2 and PRX4 in the serum of preeclampsia (PE) patients and to explore their clinical value in PE diagnosis, severity assessment, and pregnancy outcomes. A total of 110 singleton pregnant women with PE were included, consisting of 57 cases of mild PE and 53 cases of severe PE, with 110 healthy singleton pregnant women enrolled as the normal control. The baseline clinical characteristics were analyzed using chi-square test and independent samples t-test. CITED2 and PRX4 concentrations were measured by ELISA and their diagnostic efficacy for PE was evaluated through ROC curves. Multivariate logistic regression analysis was conducted to identify factors associated with adverse pregnancy outcomes in PE patients. Compared to the healthy group, CITED2 serum levels in PE patients were significantly increased, while PRX4 levels were significantly decreased. CITED2 and PRX4 can diagnose PE, distinguish between mild and severe PE, and be associate with adverse pregnancy outcomes in PE patients. The diagnostic efficacy was better when CITED2 and PRX4 were combined. The serum levels of CITED2 were further elevated and PRX4 levels were further reduced in patients with severe PE and adverse pregnancy outcomes. CITED2 was an independent risk factor and PRX4 was a protective factor for adverse pregnancy outcomes in PE patients. In conclusion, CITED2 and PRX4 can diagnose PE, assess PE severity, and are associated with PE outcomes.